{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:09:43Z","timestamp":1762506583617},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ygyno.2015.06.041","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T21:04:52Z","timestamp":1436043892000},"page":"413-418","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients"],"prefix":"10.1016","volume":"139","author":[{"given":"Katherine C.","family":"Fuh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles A.","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri S.","family":"Bevis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warner","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"ElNaggar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Blansit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Previs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Tillmanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2015.06.041_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.ygyno.2015.06.041_bb0010","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","volume":"90","author":"Buda","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2015.06.041_bb0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.06.041_bb0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","article-title":"Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial","volume":"116","author":"Markman","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"9375","key":"10.1016\/j.ygyno.2015.06.041_bb0025","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.ygyno.2015.06.041_bb0030","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2015.06.041_bb0035","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2015.06.041_bb0040","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2015.06.041_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.041_bb0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2013.09.032","article-title":"Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer","volume":"131","author":"Hagemann","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.06.041_bb0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2011.04.046","article-title":"Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers","volume":"122","author":"Kudoh","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2015.06.041_bb0060","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/cncr.25967","article-title":"Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study","volume":"117","author":"McGonigle","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2015.06.041_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2012.08.039","article-title":"Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma","volume":"128","author":"Tillmanns","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2015.06.041_bb0070","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/annonc\/mds172","article-title":"Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2015.06.041_bb0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/CAD.0b013e32833b7598","article-title":"Bevacizumab improves the delivery and efficacy of paclitaxel","volume":"21","author":"Yanagisawa","year":"2010","journal-title":"Anti-Cancer Drugs"},{"issue":"13","key":"10.1016\/j.ygyno.2015.06.041_bb0080","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2015.06.041_bb0085","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","article-title":"Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11","volume":"88","author":"Wildiers","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.ygyno.2015.06.041_bb0090","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2015.06.041_bb0095","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2015.06.041_bb0100","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.06.041_bb0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2015.06.041_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"26","key":"10.1016\/j.ygyno.2015.06.041_bb0115","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2015.06.041_bb0120","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2015.06.041_bb0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00432-010-0914-8","article-title":"Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of surviving expression","volume":"137","author":"Xiong","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.06.041_bb0130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3892\/ol.2012.553","article-title":"Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer","volume":"3","author":"Rein","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2015.06.041_bb0135","series-title":"ESGO meeting","article-title":"Every 3-week versus dose dense weekly paclitaxel combined with carboplatin +\/\u2212 bevacizumab in advanced epithelial ovarian, peritoneal, or fallopian tube cancer (GOG 262)","author":"Chan","year":"2013"},{"issue":"5s","key":"10.1016\/j.ygyno.2015.06.041_bb0140","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","author":"Gourley","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2015.06.041_bb0145","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.06.041_bb0150","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2015.02.027","article-title":"A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2015.06.041_bb0155","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T13:35:26Z","timestamp":1620826526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815300627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0090825815300627"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.041","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}